News

1 6 7 8 9 10 11 12 13 17 22
NEWS

SOTIO exercises second target option under existing collaboration with NBE-Therapeutics to develop next-generation antibody-drug conjugates

Basel, Switzerland & Prague, Czech Republic – November 7, 2019  NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation antibody-drug conjugate (ADC) under their existing license and collaboration agreement. NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of this second undisclosed target. The development will be based on NBE’s proprietary antibody drug conjugate platform, including NBE’s site-specific SMAC-technologyTM conjugation and its new, highly potent anthracycline toxin platforms. SOTIO will take global responsibility for clinical development, registration and commercialization of the ADC products.

NEWS

PPF and SOTIO invest $6.5 million in MaveriX Oncology and its lead program MVX-5005

  • PPF Group, the majority owner of SOTIO, invests $6.5 million as part of MaveriX Oncology’s $20 million Series A financing round.
  • SOTIO obtained an option to license and co-develop MVX-5005 in Europe. 
  • MaveriX is eligible to receive up to $138 million in milestone payments.
  • Norbert Prenzel, SOTIO’s Head of Business Development, will represent PPF on MaveriX Oncology’s Board of Directors.

SOTIO, together with PPF, and MaveriX Oncology, Inc., today announce the investment of PPF Group in MaveriX Oncology Inc., a private biotech company with a proprietary pipeline of targeted, small-molecule cancer chemo-immunotherapeutics. PPF has committed to investing $6.5 million in MaveriX Oncology’s ongoing Series A financing contingent on key development milestones. In total, MaveriX is aiming to secure a total of $20 million in funding and the round will remain open for additional investors to join. The proceeds will enable MaveriX to advance the company’s lead program MVX-5005 through IND-enabling studies, and complete first-in-human Phase Ia/Ib clinical trials for the treatment of solid tumors in support of clinical proof-of-concept. The company will also advance further platform programs to drug candidate selection.

NEWS

PPF expands its investment in the healthcare sector through acquisition of significant stake in T cell therapy company Autolus Therapeutics

  • Investment provides 19.2% stake in Autolus
  • Autolus is PPF’s second largest investment in the healthcare sector, after PPF’s majority-owned biotechnology company SOTIO

PPF today announces the acquisition of a 19.2% stake in Autolus Therapeutics plc, a leader in next-generation T cell programming technologies. The shares were acquired in the market through NASDAQ.